NDAORALTABLET, DELAYED RELEASE
Approved
May 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
DORYX MPC (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. Approved for gonorrhea, chlamydia, syphilis and 1 more indications. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX MPC is an oral delayed-release tablet formulation of doxycycline hyclate, a tetracycline-class antimicrobial. It treats multiple indications including gonorrhea, chlamydia, syphilis, acne vulgaris, and helicobacter pylori infection by inhibiting bacterial protein synthesis. The delayed-release formulation improves tolerability and efficacy compared to immediate-release doxycycline.
$0.146MPart D
Peak8.6 years to LOEDrug is in peak lifecycle stage with minimal Part D spending, suggesting small but stable commercial footprint requiring focused sales execution in targeted indications.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications (4)
Worked on DORYX MPC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.